Homeopathic treatment of obstructive lung diseases

Evaluating the effectiveness of adjunctive mother tinctures to individualized homeopathic treatment of chronic obstructive pulmonary diseases: an open randomized pragmatic trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/04/013394

Enrollment

Registered

2018-04-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified Health Condition 2: J449- Chronic obstructive pulmonary disease, unspecified Health Condition 3: null- Chronic Obstructive Pulmonary Diseases (COPD)

Interventions

Intervention1: Indicated homeopathic medicines in centesimal or fifty millesimal potencies plus one of the seven following mother tinctures as indicated: Cassia sophera, Justicia adhatoda, Lobelia inf

dosage and repetition depending upon the individual requirement of the cases. In 50 millesimal scale, a single medicated cane sugar globules of poppy seed size (no. 10) shall be dissolved in 90 ml dis

16 doses to be marked on the vial

each dose of 5 ml to be taken after 10 uniformly forceful downward strokes to the vial in 45 ml normal water in a clean cup, to stir well, to take 5 ml of this liquid orally, and to discard rest of th

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years 2. Both sexes 3. Suffering from mild to severe form of COPD: Mild: FEV1 >=80% predicted; FEV1/FVC Moderate: FEV1 50-79% predicted; FEV1/FVC Severe: FEV1 30-49% predicted, FEV1/FVC 4. Literate patients; ability to read English or Bengali 5. Providing written informed consent 6. Wash-out phase of conventional or other medications, if any, of 2 weeks prior to enrolment

Exclusion criteria

Exclusion criteria: 1. Patients who are too sick for consultation; e.g. very severe COPD: FEV1/FVC 2. Unwilling to take part and not giving consent to join the study 3. Unable to read patient information sheet 4. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life 5. Substance abuse and/or dependence 6. Self-reported immune-compromised state, and 7. Undergoing homeopathic treatment for any chronic disease within last 6 months

Design outcomes

Primary

Measure	Time frame
Spirometric assessment of FEV1/FVC and FEV1Timepoint: Baseline and 6 months	—

Secondary

Measure	Time frame
Clinical COPD Questionnaire (CCQ; Bengali version)Timepoint: Baseline, after 3 months, and after 6 months;COPD Assessment Test (CAT) questionnaire (Bengali version)Timepoint: Baseline, after 3 months, and after 6 months;Frequency of exacerbation (defined as acute worsening of respiratory symptoms that results in additional therapy)Timepoint: 6 months	—

Countries

India

Contacts

Public ContactAbhijit Chattopadhyay

National Institute of Homoeopathy, Ministry of AYUSH, Govt. of India

drac.nih@gmail.com7003547446

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 19, 2026